{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:17:00Z","timestamp":1759882620399,"version":"build-2065373602"},"reference-count":79,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/14760584.2024.2348609","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T21:17:59Z","timestamp":1714684679000},"page":"614-635","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination"],"prefix":"10.1080","volume":"23","author":[{"given":"Cynthia","family":"Burman","sequence":"first","affiliation":[{"name":"Pfizer Inc","place":["Collegeville, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Knuf","sequence":"additional","affiliation":[{"name":"Worms Clinic","place":["Worms, Germany"]},{"name":"University Medicine Mainz","place":["Mainz, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-9446","authenticated-orcid":false,"given":"Marco Aurelio P.","family":"S\u00e1fadi","sequence":"additional","affiliation":[{"name":"Santa Casa de S\u00e3o Paulo School of Medical Sciences","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[{"name":"Pfizer Ltd","place":["Surrey, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2014.11.006"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.09.010409"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.062"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268823000328"},{"key":"e_1_3_7_7_1","unstructured":"European Centre for Disease Prevention and Control. Invasive meningococcal disease annual epidemiological report for 2018. 2022."},{"key":"e_1_3_7_8_1","unstructured":"Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report 2016 [Internet]. [cited 2022 Oct 6]. Available from: https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report.pdf"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0828-8"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8101521"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.05.079"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00751"},{"key":"e_1_3_7_13_1","volume-title":"Full prescribing information","author":"PENBRAYA (meningococcal groups A, B, C, W, and Y vaccine)","year":"2023","unstructured":"PENBRAYA (meningococcal groups A, B, C, W, and Y vaccine). Full prescribing information. New York (NY): Pfizer Inc; 2023."},{"key":"e_1_3_7_14_1","volume-title":"Worldwide regulatory status \u2013 Nimenrix","author":"Data on File","year":"2020","unstructured":"Data on File. Worldwide regulatory status \u2013 Nimenrix. New york (USA): Pfizer Inc; 2020."},{"key":"e_1_3_7_15_1","volume-title":"Summary of product characteristics","author":"Nimenrix\u00ae (meningococcal groups A, C, W-135 and Y conjugate vaccine)","year":"2022","unstructured":"Nimenrix\u00ae (meningococcal groups A, C, W-135 and Y conjugate vaccine). Summary of product characteristics. Bruxelles (BG): Pfizer Europe MA EEIG; 2022."},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.09.077"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1855952"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182054ab9"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.2.14068"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-116"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.10.064"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.03.009"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2020.1745070"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.03.043"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1307"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1593082"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.10.5.780-786.2003"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.051"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.02.048"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1696582"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2307.170236"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab791"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05104-5"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.049"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.02.030"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1746110"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.11.048"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1744363"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.20229"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1138-y"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2012.10.001"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22165"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22166"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1058457"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1163455"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1248009"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000897"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu052.794"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000866"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31828693c5"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001123"},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.04.064"},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002334"},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.013"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.06.053"},{"key":"e_1_3_7_56_1","unstructured":"ClinicalTrials.gov. A study to evaluate a booster dose of MenACWY-TT vaccine administered 10 years after healthy subjects aged 11-17 years received either MenACWY-TT vaccine (Nimenrix(registered)) or Mencevax ACWY (Registered) [internet]. [cited 2024 Mar 21]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03189745"},{"key":"e_1_3_7_57_1","unstructured":"World Health Organization. Meningococcal meningitis [Internet]. [cited 2024 Jan 5]. Available from: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/diseases\/meningitis"},{"key":"e_1_3_7_58_1","unstructured":"European Centre for Disease Prevention and Control. ECDC vaccine scheduler [Internet]. [cited 2024 Jan 4]. Available from: https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1"},{"key":"e_1_3_7_59_1","unstructured":"World Health Organization. Vaccination schedule for meningococcal disease [Internet]. [cited 2024 Jan 4]. Available from: https:\/\/immunizationdata.who.int\/pages\/schedule-by-disease\/meningococcal.html?ISO_3_CODE=&TARGETPOP_GENERAL="},{"key":"e_1_3_7_60_1","unstructured":"Federa\u00e7\u00e3o Brasileira de Ginecologia e Obstetr\u00edcia. Febrasgo position statement [Internet]. [cited 2023 May 17]. Available from: https:\/\/www.scielo.br\/j\/rbgo\/a\/6YkW3TrLTXRBQNmNcYH6Mtb\/?format=pdf&lang=en"},{"key":"e_1_3_7_61_1","unstructured":"Government of Canada. Meningococcal vaccines: Canadian Immunization Guide [Internet]. [cited 2024 Jan 4]. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-13-meningococcal-vaccine.html"},{"key":"e_1_3_7_62_1","unstructured":"NZ Ministry of Health. 13. Meningococcal disease [Internet]. [cited 2024 Jan 4]. Available from: https:\/\/www.health.govt.nz\/our-work\/immunisation-handbook-2020\/13-meningococcal-disease#12-5"},{"key":"e_1_3_7_63_1","unstructured":"Kingdom of Saudi Arabia Ministry of Health. Immunization [Internet]. [cited 2024 Jan 4]. Available from: https:\/\/www.moh.gov.sa\/en\/HealthAwareness\/EducationalContent\/vaccination\/Pages\/vaccination1.aspx"},{"key":"e_1_3_7_64_1","unstructured":"NHS. NHS vaccinations and when to have them [Internet]. [cited 2024 Jan 3]. Available from: https:\/\/www.nhs.uk\/conditions\/vaccinations\/nhs-vaccinations-and-when-to-have-them\/"},{"key":"e_1_3_7_65_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6909a1"},{"issue":"3","key":"e_1_3_7_66_1","first-page":"72","article-title":"Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010","volume":"60","year":"2011","unstructured":"Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2011;60(3):72\u201376.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_7_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-019-01129-z"},{"key":"e_1_3_7_68_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES2015.20.28.21188"},{"key":"e_1_3_7_69_1","unstructured":"Public Health England. Vaccine update issue 256. 2016 Dec. https:\/\/www.gov.uk\/government\/publications\/vaccine-update-issue-256-december-2016"},{"key":"e_1_3_7_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(21)00335-7"},{"key":"e_1_3_7_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.09.050"},{"key":"e_1_3_7_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.11.075"},{"key":"e_1_3_7_73_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2251825"},{"key":"e_1_3_7_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/20477724.2021.1972663"},{"key":"e_1_3_7_75_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19074035"},{"key":"e_1_3_7_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-509"},{"key":"e_1_3_7_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70251-6"},{"key":"e_1_3_7_78_1","unstructured":"National Health Service. MenACWY vaccine overview [Internet]. [cited 2023 Jun 2]. Available from: https:\/\/www.nhs.uk\/conditions\/vaccinations\/men-acwy-vaccine\/"},{"key":"e_1_3_7_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00609-9"},{"key":"e_1_3_7_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1968214"},{"key":"e_1_3_7_81_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10080928"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2024.2348609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:48:16Z","timestamp":1759830496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2024.2348609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/14760584.2024.2348609"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2024.2348609","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"type":"print","value":"1476-0584"},{"type":"electronic","value":"1744-8395"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}